Bioheart's President/CEO Mike Tomas Inducted Into Miami Dade College Hall of Fame
03 Mayo 2012 - 6:00AM
Bioheart, Inc. (BHRT.OB) announced today that Mike Tomas, the
company's President/CEO, has been named a 2012 Hall of Famer by
Miami Dade College (MDC). Tomas is one of 25 alumni presented with
its top recognition, and induction into the MDC's Alumni Hall of
Fame, whose honorees are many of the nation's premier
entrepreneurs, professionals, public servants, artists and other
leaders.
"Our Hall of Fame honorees span a wide range of professions and
possibilities," said MDC President Dr. Eduardo J. Padrón. "Their
success inspires us with optimism for what future generations of
Miami Dade College students will achieve and reminds us of
education's ability to alter individual lives, families and
communities."
Mike Tomas was appointed as Bioheart's President, CEO and a
Director on June 19, 2010. For the past 11 years, Tomas served as
President of The ASTRI Group, an early stage private equity
investment company in Florida with an investment in Bioheart. In
2003, he joined Bioheart's Board of Directors as the independent
representative of The ASTRI Group. Prior to this, Tomas held
ascending executive positions including Chief Marketing Officer at
Avantel, a $1 billion dollar joint venture with MCI. He currently
sits on the boards of Perimeter Internetworking, Avisena and Total
Home Health. He is also the current chairman of the Global
Entrepreneurship Center at Florida International University and a
founding coach/mentor at the University of Miami's Launch Pad at
the Toppel Center. Mike holds a Masters of Business
Administration from the University of Miami, a Bachelor degree from
Florida International University and an Associate degree from Miami
Dade College.
Each year, new alumni who have attained great success and made
significant contributions in their fields are selected to join
MDC's Hall of Fame's prestigious ranks. The impressive inductees
represent all spectrums of the community, from health care and
public service to communications and engineering. Miami Dade
College will honor some of its outstanding alumni at the 10th
annual Hall of Fame Gala, being held May 10, 2012 at 6pm at the
Hilton Miami Downtown.
Today, more than 174,000 students attend Miami Dade College, a
state-supported college with eight campuses and numerous outreach
centers. Miami Dade College is one of the largest institutions of
higher education in the United States and one of the most highly
regarded colleges in the nation. For more information, visit
www.mdc.edu.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within
the cardiovascular sector of the cell technology industry
delivering cell therapies and biologics that help address
congestive heart failure, lower limb ischemia, chronic heart
ischemia, acute myocardial infarctions and other issues. Bioheart's
goals are to cause damaged tissue to be regenerated, when possible,
and to improve a patient's quality of life and reduce health care
costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery,
development and, subject to regulatory approval, commercialization
of autologous cell therapies for the treatment of chronic and acute
heart damage and peripheral vascular disease. Its leading product,
MyoCell, is a clinical muscle-derived cell therapy designed to
populate regions of scar tissue within a patient's heart with new
living cells for the purpose of improving cardiac function in
chronic heart failure patients. For more information on Bioheart,
visit www.bioheartinc.com, or visit us on Facebook: Bioheart and
Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters
contained herein, statements made in this press release are
forward-looking statements. Without limiting the generality of the
foregoing, words such as "may," "will," "to," "plan," "expect,"
"believe," "anticipate," "intend," "could," "would," "estimate," or
"continue" or the negative other variations thereof or comparable
terminology are intended to identify forward-looking
statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Also, forward-looking statements
represent our management's beliefs and assumptions only as of the
date hereof. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
The Company is subject to the risks and uncertainties described
in its filings with the Securities and Exchange Commission,
including the section entitled "Risk Factors" in its Annual Report
on Form 10-K for the year ended December 31, 2010, and its
Quarterly Report on Form 10-Q for the quarter ended December 31,
2011.
CONTACT: Jeanne A. Becker
Becker Public Relations
2506 Ponce de Leon Blvd.
Coral Gables, FL 33134
Telephone 305/444-2181 X 222
Email: jbecker@beckerpublicrelations.com
US Stem Cell (CE) (USOTC:USRM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
US Stem Cell (CE) (USOTC:USRM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024